Cell and Gene Therapies: Accelerating uptake
Cell and gene therapies (CAGTs) are delivering on the promise of personalised medicines, meeting high unmet need and delivering powerful and curative treatments. So why is uptake so slow? The obstacles are diverse with the low volume of patients impacting clinical research, evidence generation and manufacturing efficiency, while cost, reimbursement challenges and low HCP knowledge/confidence are all limiting wider adoption. What can be done? How pharma can rethink its commercial and business models is explored by CAGT sector experts in this report.
Companies
Amgen, Novartis, Bristol Myers Squibb, Astellas, Spark Therapeutics, Bluebird Bio, Santen, Kite Pharma, Taysha Gene Therapies, Autolus
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook